We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New High Precision Kits Available for Gyros Immunoassay Platform

By LabMedica International staff writers
Posted on 31 Mar 2014
Print article
Caption: EMD Millipore's new high-precision GyroMark HT immunoassays of important biomarkers for use on the Gyros automated, high-throughput platform (Image courtesy of EMD Millipore and Gyros).
Caption: EMD Millipore's new high-precision GyroMark HT immunoassays of important biomarkers for use on the Gyros automated, high-throughput platform (Image courtesy of EMD Millipore and Gyros).
New ready-to-use kits designed for the Gyros high-throughput immunoassay platform will enable generation of high quality data for clinical research and drug development faster than typical ELISA kits.

EMD Millipore, life sciences division of Merck KGaA (Darmstadt, Germany) has released its initial set of "GyroMark HT" immunoassay kits, 5 new kits designed specifically for use on the "Gyrolab xP" workstation from Gyros AB (Uppsala, Sweden). Traditional ELISAs can consume significant time, sample, and reagents. With the automated, walk-away system from Gyros, up to 480 data points can be generated in a single run using less sample and reagents. The initial launch includes assays for important metabolic and toxicity biomarkers, such as GLP-1, insulin, clusterin, and KIM-1. EMD Millipore plans to release additional kits this year and offers custom kits for companies with specific needs or unique or novel antibodies.

The GyroMark HT kits are fully qualified for reliable use in clinical research and feature simple, automated, nanoliter-scale assays requiring as little as 1 µL of sample – with assay precision and accuracy that meet or exceed ELISA performance. “We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” said Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

Employing microfluidic technology with parallel processing, the Gyros platform offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays further provide: accuracy over a four-log dynamic range (compared to two logs for ELISAs); elimination of cross-talk and plate position artifacts; and simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference.

Maria Hjortsmark, Gyros’ Global Marketing Director, commented, “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale, and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits to further reduce time-to-results, freeing up analyst time and offering an easier route to robust, reproducible data.”

Related Links:

Gyros
EMD Millipore


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.